Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04908228
Title Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naive Patients With CLL (FIGHT)
Acronym FIGHT
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Paolo Ghia
Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST